Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tevogen Bio Holdings ( (TVGN) ) has shared an announcement.
On June 27, 2025, Tevogen Bio Holdings Inc. approved restricted stock award grants, including 8,000,000 shares to CEO Dr. Ryan Saadi, bringing the total outstanding shares to 193,693,433. The shares will vest over several years, with specific conditions for vesting and restrictions on transfer prior to vesting, impacting the company’s stock management and executive compensation strategy.
The most recent analyst rating on (TVGN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Tevogen Bio Holdings stock, see the TVGN Stock Forecast page.
Spark’s Take on TVGN Stock
According to Spark, TipRanks’ AI Analyst, TVGN is a Underperform.
Tevogen Bio Holdings faces substantial financial risks due to consistent losses and high leverage, which are typical in its industry. Technical analysis indicates a bearish trend, and valuation metrics show speculative investment characteristics. However, the recent corporate event involving a strategic agreement provides a positive outlook for operational advancements, slightly balancing the financial and technical concerns.
To see Spark’s full report on TVGN stock, click here.
More about Tevogen Bio Holdings
Average Trading Volume: 970,319
Technical Sentiment Signal: Sell
Current Market Cap: $225M
For a thorough assessment of TVGN stock, go to TipRanks’ Stock Analysis page.